Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

The purpose of this study is to leverage two sources of real-world data (RWD) to assess the effectiveness of troriluzole after three years of treatment in patients with SCA by comparison to an external control of untreated patients who were followed in a natural history cohort. Real world evidence of effectiveness will be assessed from the RWD sources to examine the treatment effects of toriluzole in SCA out to 3 years. Progression rates of SCA differ by genotype and long-term follow-up is needed to assess for potential efficacy in this rare disease.

NCT Number	NCT06529146
Lead Sponsor	Biohaven Therapeutics Ltd.
Conditions	Spinocerebellar Ataxias
Enrollment	909 participants
Start Date	2019-03-18
Primary Completion	2024-09-06 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-09